Skip to Main Content

Paper Details

Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma.
Oncogene
22
2014
-, AKT, FKHR, IGF, IGF1/2, IGF1R, IGF1R antibody, IGF1R antibody-resistant RMS cells, IGF2, IGFBP2, PAX3, PI3K, Phosphatidylinositide 3-kinases, Protein kinase B, RMS, RMS cells, insulin-like growth factor, insulin-like growth factor-1 receptor, mTOR, mammalian target of, patients, rapamycin, resistant cells, resistant lines, rhabdomyosarcoma, sarcoma, tumor, tumor cells
Aminopyridines, Animals, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Cell Line, Tumor, Down-Regulation, Drug Resistance, Neoplasm, Female, Gene Expression Regulation, Neoplastic, Humans, Insulin-Like Growth Factor Binding Protein 2, Mice, Mice, SCID, Molecular Targeted Therapy, Morpholines, Pyrimidines, Receptor, IGF Type 1, Rhabdomyosarcoma, Treatment Failure, Xenograft Model Antitumor Assays
Author NameAffiliation
Zhigang KangCenter for Cancer Research, National Cancer Institute, Inc.
Zhigang KangCenter for Cancer Research, National Cancer Institute, Inc.
Yunkai YuCenter for Cancer Research, National Cancer Institute
Yunkai YuCenter for Cancer Research, National Cancer Institute
Yuelin J ZhuCenter for Cancer Research, National Cancer Institute
Yuelin J ZhuCenter for Cancer Research, National Cancer Institute
Sean DavisCenter for Cancer Research, National Cancer Institute
Susan R DavisCenter for Cancer Research, National Cancer Institute
Robert L WalkerCenter for Cancer Research, National Cancer Institute
Robert L WalkerCenter for Cancer Research, National Cancer Institute
Paul S MeltzerCenter for Cancer Research, National Cancer Institute
Paul S MeltzerCenter for Cancer Research, National Cancer Institute
Lee J HelmanCenter for Cancer Research, National Cancer Institute
Lee J HelmanCenter for Cancer Research, National Cancer Institute
Liang CaoCenter for Cancer Research, National Cancer Institute
Liang CaoCenter for Cancer Research, National Cancer Institute
  • 1 - 16

Datasets

Release 1.2